Recently published studies and currently available evidence do not implicate Xenotropic Murine Leukemia Virus-Related Virus (XMRV) and other Murine Leukemia Virus-Related Viruses (MLRV) in Chronic Fatigue Syndrome. On the basis of existing data, donor screening for XMRV will not be indicated. No risk to transfusion recipients has been identified to date. The AABB Interorganizational Task Force on XMRV reiterates that individuals who have a medical diagnosis of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) refrain from donating blood or blood components. This recommendation is based on concerns for the health of the potential donor.

AABB's current policy states that blood-collecting organizations — using donor education materials available at the donation site — should actively discourage potential donors who have been diagnosed with CFS from donating blood or blood components. In light of recently published studies, and consistent with the Task Force charges, the Task Force will re-evaluate this policy as it applies to potential donors who have received a medical diagnosis of CFS, but now feel well. Donor eligibility determinations not required by FDA regulations or AABB Standards are subject to the discretion of the collection facility's medical director.

Background information regarding the Task Force, its charges, and AABB policy on this issue is available at http://www.aabb.org/pressroom/statements/Pages/statement021011.aspx.

Media inquiries may be directed to the AABB Public Relations Department via email (publicrelations@aabb.org) or by phone (301-215-6526).